Billiontoone (NASDAQ:BLLN) CEO Sells $313,016.22 in Stock

Billiontoone, Inc. (NASDAQ:BLLN) CEO Oguzhan Atay sold 3,183 shares of the stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $98.34, for a total value of $313,016.22. Following the transaction, the chief executive officer owned 3,183 shares in the company, valued at approximately $313,016.22. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oguzhan Atay also recently made the following trade(s):

• On Thursday, October 15th, Oguzhan Atay sold 5,150 shares of Billiontoone stock. The stock was sold at an average price of $100.23, for a total value of $516,184.50.
• On Wednesday, October 14th, Oguzhan Atay sold 2,667 shares of Billiontoone stock. The shares were sold at an average price of $98.00, for a total value of $261,366.00.
• On Monday, October 12th, Oguzhan Atay sold 2,667 shares of Billiontoone stock. The shares were sold at an average price of $97.61, for a total value of $260,325.87.
• On Monday, October 12th, Oguzhan Atay sold 16,667 shares of Billiontoone stock. The shares were sold at an average price of $93.79, for a total value of $1,563,197.93.
• On Monday, September 28th, Oguzhan Atay sold 2,666 shares of Billiontoone stock. The shares were sold at an average price of $120.64, for a total value of $321,626.24.
• On Monday, September 28th, Oguzhan Atay sold 8,333 shares of Billiontoone stock. The stock was sold at an average price of $120.64, for a total value of $1,005,293.12.
• On Monday, September 14th, Oguzhan Atay sold 5,332 shares of Billiontoone stock. The stock was sold at an average price of $98.00, for a total value of $522,536.00.
• On Monday, September 14th, Oguzhan Atay sold 24,999 shares of Billiontoone stock. The stock was sold at an average price of $100.32, for a total value of $2,507,899.68.
• On Monday, August 3rd, Oguzhan Atay sold 12,500 shares of Billiontoone stock. The shares were sold at an average price of $137.37, for a total transaction of $1,717,125.00.
• On Monday, August 3rd, Oguzhan Atay sold 32,500 shares of Billiontoone stock. The shares were sold at an average price of $136.95, for a total transaction of $4,450,875.00.

Billiontoone Stock Performance

Shares of BLLN stock traded down $4.61 on Friday, hitting $98.12. The company’s stock had a trading volume of 605,635 shares, compared to its average volume of 654,157. The company has a debt-to-equity ratio of 0.17, a quick ratio of 11.31 and a current ratio of 11.69. The stock’s 50 day moving average is $100.99 and its 200-day moving average is $101.58. Billiontoone, Inc. has a fifty-two week low of $61.96 and a fifty-two week high of $150.44. The company has a market capitalization of $4.63 billion and a PE ratio of 140.17.

Billiontoone (NASDAQ:BLLN) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.15 EPS for the quarter, hitting analysts’ consensus estimates of $0.15. The business had revenue of $109.45 million for the quarter. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. Equities research analysts expect that Billiontoone, Inc. will post 0.80 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Billiontoone

Several institutional investors and hedge funds have recently bought and sold shares of BLLN. Wasatch Advisors LP grew its stake in Billiontoone by 40.2% during the second quarter. Wasatch Advisors LP now owns 518,084 shares of the company’s stock worth $62,160,000 after buying an additional 148,446 shares in the last quarter. Emerald Advisers LLC raised its position in shares of Billiontoone by 26.8% in the 1st quarter. Emerald Advisers LLC now owns 239,562 shares of the company’s stock valued at $18,911,000 after buying an additional 50,613 shares in the last quarter. Emerald Mutual Fund Advisers Trust raised its position in shares of Billiontoone by 11.9% in the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 132,206 shares of the company’s stock valued at $10,436,000 after buying an additional 14,072 shares in the last quarter. Perceptive Advisors LLC raised its position in shares of Billiontoone by 26.1% in the 1st quarter. Perceptive Advisors LLC now owns 91,812 shares of the company’s stock valued at $7,248,000 after buying an additional 19,000 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new stake in shares of Billiontoone during the 1st quarter worth approximately $4,046,000.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Weiss Ratings cut shares of Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday, October 8th. Zacks Research upgraded Billiontoone from a “strong sell” rating to a “hold” rating in a research note on Friday, October 2nd. Wall Street Zen lowered Billiontoone from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Canaccord Genuity Group began coverage on Billiontoone in a research note on Wednesday, September 2nd. They set a “buy” rating and a $120.00 price objective on the stock. Finally, Guggenheim lifted their price objective on Billiontoone from $125.00 to $128.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Seven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Billiontoone has an average rating of “Moderate Buy” and an average price target of $126.25.

About Billiontoone

BillionToOne, Inc (NASDAQ:BLLN) is a molecular diagnostics company that develops blood-based genetic tests designed to provide more information from small amounts of cell-free DNA. The company’s platform uses proprietary molecular counting technology to improve the sensitivity and accuracy of diagnostic testing.

BillionToOne’s primary business is reproductive health testing. Its UNITY portfolio is designed to support prenatal screening, including testing for chromosomal conditions and single-gene disorders, and is intended to provide physicians and expectant parents with information from a maternal blood sample.